Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What is dabrafenib mesylate msn patent issue?
Sun pharma bortezomib?
Stribild expiry date?
Drugpatentwatch trametinib?
How does iron rich food intake impact lipitor's efficacy?

Gabapentin expired?

See the DrugPatentWatch profile for Gabapentin

What does “gabapentin expired” mean?

It usually refers to one of two things: whether gabapentin’s patent/market exclusivity has ended, or whether an individual bottle/lot has reached its labeled expiration date. These are different questions with different answers.

Has gabapentin’s patent or exclusivity expired?

The specific “expired?” status depends on which regulatory period you mean and which version/product (for example, immediate‑release vs. extended‑release) and country. Gabapentin is an older, widely used medicine and is available as generic products in many markets, which strongly suggests that key manufacturer exclusivity for the original brand has ended. (To answer precisely, you’d need the brand name, dosage form, and the country/region you mean.)

Is the gabapentin bottle you have still safe to use after the expiration date?

Using medicine after its expiration date is generally not recommended because the manufacturer can’t guarantee potency and stability past that date. The risk varies by product and storage conditions, but the safe approach is to not take expired tablets/capsules and to contact a pharmacist or prescriber for a replacement.

What to do if you think your gabapentin is expired

If it’s past the printed expiration date, ask your pharmacist about replacing it or using a new prescription refill. If you’re trying to stretch doses because you’re worried about running out, contact your prescriber for guidance rather than changing the regimen on your own.

How to check expiration accurately

Check the expiration date printed on the specific label you have (including whether there’s an “EXP” date and, if applicable, lot details). Also confirm the formulation (for example, immediate‑release vs extended‑release) because expiration and stability labeling can differ by product.

If you tell me these details, I can answer more precisely

1) Which country/state are you in?
2) Brand name (if any) and whether it’s immediate‑release or extended‑release
3) Are you asking about the medication’s legal exclusivity/patent, or the expiration date on your bottle?



Other Questions About Gabapentin :

is gabapentin made in the united states Gabapentin brand name? Drugs com gabapentin brand names? Gabapentin class? Gabapentin capsules ip 100mg? What are the withdrawal symptoms of gabapentin? Gabapentin brand names?

AI-Drug Label Prescribing Information Alignment Report

95
95%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI evaluation of the claim '2.1 Dosage for Postherpetic Neuralgia' is fully supported by the provided FDA label excerpts from Sections 2.1 and 14.1, with no contradictions identified.

Category Scores

Dosage
95
Excellent

Accurate Statements

In adults with postherpetic neuralgia, GABARONE may be initiated on Day 1 as a single 300 mg dose, Day 2 as 600 mg/day (300 mg two times a day), and Day 3 as 900 mg/day (300 mg three times a day).
SECTION 2.1 — DOSAGE FOR POSTHERPETIC NEURALGIA
The dose can subsequently be titrated up as needed for pain relief to a dose of 1800 mg/day (600 mg three times a day).
SECTION 2.1 — DOSAGE FOR POSTHERPETIC NEURALGIA
Clinical studies demonstrated efficacy over doses from 1800 mg/day to 3600 mg/day, and additional benefit of doses greater than 1800 mg/day was not demonstrated.
SECTION 2.1 — DOSAGE FOR POSTHERPETIC NEURALGIA
The studies included titration to a maximum of 900 mg/day over 3 days before titrating in 600 to 1200 mg/day increments at 3- to 7-day intervals to the target dose over 3 to 4 weeks.
SECTION 14.1 — POSTHERPETIC NEURALGIA (Dose arms / study design)

Unsupported Statements

Contradictions

Important Omissions

No material omission related to evaluating the specific claim about Section 2.1 dosage/titration for postherpetic neuralgia.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The AI response only evaluated and summarized dosing/titration information from the provided label excerpts for the specified claim, without adding safety guidance, contraindications, or other treatment recommendations beyond the cited dosing content.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement